The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease

Mahmoud Mosli, Kristopher Croome, Karim Qumosani, Bandar Al-Judaibi, Melanie Beaton, Paul Marotta, Natasha Chandok

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Immunosuppressive therapies are indicated following liver transplantation (LT) to prevent graft loss through rejection, and these same agents also may have a role in the management of inflammatory bowel disease (IBD). The aims of this study were to examine the effects of immunosuppression following LT on IBD activity and to identify markers of IBD control post-LT in patients with IBD who underwent LT for primary sclerosing cholangitis (PSC). A retrospective analysis of all adult patients with a pre-LT diagnosis of IBD who underwent LT for PSC over a 15-year period was performed. The primary outcome was IBD activity based on symptomatology and endoscopic assessment. Secondary outcomes included recipient mortality and post-LT development of colorectal cancer or small bowel lymphoma. A total of 105 patients underwent LT for PSC, and IBD was diagnosed in 27 (26%) pre-LT. Patients were followed for a mean of 88.5 months. Fourteen (52%) patients had stable IBD, 6 (22%) had worsening disease, and 7 (26%) had clinical improvement after LT. Colorectal cancer developed in 2 (7%) patients, and small bowel lymphoma developed in 1 (4%) patient. The absence of additional maintenance therapy for IBD was found to be associated with good outcome for IBD control. The use of either infliximab (Remicade, Janssen Biotech) or corticosteroids to control IBD post-LT was associated with poor outcome. Most patients with PSC and IBD had a stable course of IBD post-LT. The need for infliximab or additional or prolonged corticosteroids after LT appears to be a surrogate marker of aggressive disease.

Original languageEnglish (US)
Pages (from-to)434-441
Number of pages8
JournalGastroenterology and Hepatology
Volume9
Issue number7
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Inflammatory Bowel Diseases
Liver Transplantation
Colorectal Neoplasms
Lymphoma
Adrenal Cortex Hormones
Immunosuppressive Agents
Immunosuppression

Keywords

  • Inflammatory bowel disease
  • Liver transplantation
  • Predictors of outcome
  • Primary sclerosing cholangitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Mosli, M., Croome, K., Qumosani, K., Al-Judaibi, B., Beaton, M., Marotta, P., & Chandok, N. (2013). The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease. Gastroenterology and Hepatology, 9(7), 434-441.

The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease. / Mosli, Mahmoud; Croome, Kristopher; Qumosani, Karim; Al-Judaibi, Bandar; Beaton, Melanie; Marotta, Paul; Chandok, Natasha.

In: Gastroenterology and Hepatology, Vol. 9, No. 7, 07.2013, p. 434-441.

Research output: Contribution to journalArticle

Mosli, M, Croome, K, Qumosani, K, Al-Judaibi, B, Beaton, M, Marotta, P & Chandok, N 2013, 'The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease', Gastroenterology and Hepatology, vol. 9, no. 7, pp. 434-441.
Mosli, Mahmoud ; Croome, Kristopher ; Qumosani, Karim ; Al-Judaibi, Bandar ; Beaton, Melanie ; Marotta, Paul ; Chandok, Natasha. / The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease. In: Gastroenterology and Hepatology. 2013 ; Vol. 9, No. 7. pp. 434-441.
@article{f9fb3cd2e31b4e6e9376c9cf2f07cfeb,
title = "The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease",
abstract = "Immunosuppressive therapies are indicated following liver transplantation (LT) to prevent graft loss through rejection, and these same agents also may have a role in the management of inflammatory bowel disease (IBD). The aims of this study were to examine the effects of immunosuppression following LT on IBD activity and to identify markers of IBD control post-LT in patients with IBD who underwent LT for primary sclerosing cholangitis (PSC). A retrospective analysis of all adult patients with a pre-LT diagnosis of IBD who underwent LT for PSC over a 15-year period was performed. The primary outcome was IBD activity based on symptomatology and endoscopic assessment. Secondary outcomes included recipient mortality and post-LT development of colorectal cancer or small bowel lymphoma. A total of 105 patients underwent LT for PSC, and IBD was diagnosed in 27 (26{\%}) pre-LT. Patients were followed for a mean of 88.5 months. Fourteen (52{\%}) patients had stable IBD, 6 (22{\%}) had worsening disease, and 7 (26{\%}) had clinical improvement after LT. Colorectal cancer developed in 2 (7{\%}) patients, and small bowel lymphoma developed in 1 (4{\%}) patient. The absence of additional maintenance therapy for IBD was found to be associated with good outcome for IBD control. The use of either infliximab (Remicade, Janssen Biotech) or corticosteroids to control IBD post-LT was associated with poor outcome. Most patients with PSC and IBD had a stable course of IBD post-LT. The need for infliximab or additional or prolonged corticosteroids after LT appears to be a surrogate marker of aggressive disease.",
keywords = "Inflammatory bowel disease, Liver transplantation, Predictors of outcome, Primary sclerosing cholangitis",
author = "Mahmoud Mosli and Kristopher Croome and Karim Qumosani and Bandar Al-Judaibi and Melanie Beaton and Paul Marotta and Natasha Chandok",
year = "2013",
month = "7",
language = "English (US)",
volume = "9",
pages = "434--441",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "7",

}

TY - JOUR

T1 - The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease

AU - Mosli, Mahmoud

AU - Croome, Kristopher

AU - Qumosani, Karim

AU - Al-Judaibi, Bandar

AU - Beaton, Melanie

AU - Marotta, Paul

AU - Chandok, Natasha

PY - 2013/7

Y1 - 2013/7

N2 - Immunosuppressive therapies are indicated following liver transplantation (LT) to prevent graft loss through rejection, and these same agents also may have a role in the management of inflammatory bowel disease (IBD). The aims of this study were to examine the effects of immunosuppression following LT on IBD activity and to identify markers of IBD control post-LT in patients with IBD who underwent LT for primary sclerosing cholangitis (PSC). A retrospective analysis of all adult patients with a pre-LT diagnosis of IBD who underwent LT for PSC over a 15-year period was performed. The primary outcome was IBD activity based on symptomatology and endoscopic assessment. Secondary outcomes included recipient mortality and post-LT development of colorectal cancer or small bowel lymphoma. A total of 105 patients underwent LT for PSC, and IBD was diagnosed in 27 (26%) pre-LT. Patients were followed for a mean of 88.5 months. Fourteen (52%) patients had stable IBD, 6 (22%) had worsening disease, and 7 (26%) had clinical improvement after LT. Colorectal cancer developed in 2 (7%) patients, and small bowel lymphoma developed in 1 (4%) patient. The absence of additional maintenance therapy for IBD was found to be associated with good outcome for IBD control. The use of either infliximab (Remicade, Janssen Biotech) or corticosteroids to control IBD post-LT was associated with poor outcome. Most patients with PSC and IBD had a stable course of IBD post-LT. The need for infliximab or additional or prolonged corticosteroids after LT appears to be a surrogate marker of aggressive disease.

AB - Immunosuppressive therapies are indicated following liver transplantation (LT) to prevent graft loss through rejection, and these same agents also may have a role in the management of inflammatory bowel disease (IBD). The aims of this study were to examine the effects of immunosuppression following LT on IBD activity and to identify markers of IBD control post-LT in patients with IBD who underwent LT for primary sclerosing cholangitis (PSC). A retrospective analysis of all adult patients with a pre-LT diagnosis of IBD who underwent LT for PSC over a 15-year period was performed. The primary outcome was IBD activity based on symptomatology and endoscopic assessment. Secondary outcomes included recipient mortality and post-LT development of colorectal cancer or small bowel lymphoma. A total of 105 patients underwent LT for PSC, and IBD was diagnosed in 27 (26%) pre-LT. Patients were followed for a mean of 88.5 months. Fourteen (52%) patients had stable IBD, 6 (22%) had worsening disease, and 7 (26%) had clinical improvement after LT. Colorectal cancer developed in 2 (7%) patients, and small bowel lymphoma developed in 1 (4%) patient. The absence of additional maintenance therapy for IBD was found to be associated with good outcome for IBD control. The use of either infliximab (Remicade, Janssen Biotech) or corticosteroids to control IBD post-LT was associated with poor outcome. Most patients with PSC and IBD had a stable course of IBD post-LT. The need for infliximab or additional or prolonged corticosteroids after LT appears to be a surrogate marker of aggressive disease.

KW - Inflammatory bowel disease

KW - Liver transplantation

KW - Predictors of outcome

KW - Primary sclerosing cholangitis

UR - http://www.scopus.com/inward/record.url?scp=84880865657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880865657&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84880865657

VL - 9

SP - 434

EP - 441

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 7

ER -